Volume 17, Issue 61 (Sep 2007)                   J Mazandaran Univ Med Sci 2007, 17(61): 12-19 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rashidi ghader F, Kosaryan M, Karami H. Assessment of the effect of combination therapy with Deferiprone & Desferrioxamine on cardiac complications in major Thalassemia. J Mazandaran Univ Med Sci. 2007; 17 (61) :12-19
URL: http://jmums.mazums.ac.ir/article-1-261-en.html
Abstract:   (10294 Views)
Background and Purpose: Cardiac complications in major thalassemia are the most debilitating problem among them. Iron chelating with desferrioxamine, may be difficult or inadequate. The aim of this research is to evaluate the effect of combination therapy with the two drugs "deferiprone & desferrioxamine" on cardiac complications in major thalassemia.
Materials and Methods: In a clinical trial study (before & after), 47(24men and 23 women) patients with major thalassemia referred to Booali research center,10 to 35 years old, all of whom were undertaken combination therapy with deferiprone & desferrioxamine, enrolled in this study. Echocardiography was performed for all patients before & after at least 6 months of combination therapy. Echocardiographic systolic & diastolic function indices including LVEF, EPSS, CI&E/A, EF slope & MPI, as well as presence of arrhythmia were obtained. The data were analyzed by paired T Test & Pearson correlation.
Results: There were significant changes in ferritin, systolic function& MPI, indicating statistically significant improvement. Ferritin decreased to 3306±1347ng/ml from 4489±1607ng/ml (p=0.000). LVEF increased to 69.7±2.6% from 67.6±3.9% (p=0.04). EPSS decreased to 2.9±1.3mm from 3.9±2.1mm (p=0.004). Cardiac Index increased to 3.6±0.18 from 3.5±0.3 (p=0.02). MPI decreased to 0.33±0.05 from 0.37±0.06 (p=0.03). Arrhythmia & diastolic function were also slightly improved which were statistically nonsignificant.
Conclusion: The results showed that combination therapy with the two drugs deferiprone & desferrioxamine led to decrease ferritin level and improve systolic function in patients with major thalassemia.
Full-Text [PDF 264 kb]   (1861 Downloads)    
Type of Study: Research(Original) |

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2019 All Rights Reserved | Journal of Mazandaran University of Medical Sciences

Designed & Developed by : Yektaweb